Overview

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Remdesivir